Price
$20.59-3.01%Social Signal Score
Analyst Ratings
4 analystsRevenue
$17.18M+344.37%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert Joseph Ball
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Employees
- 74
- Beta
- -1.77
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 8.08
Financials
Revenue
$17.18M+344.4%Net Income
$-10.15MEBITDA
$-10.15MFree Cash Flow
$-9.55MEPS (diluted)
$-0.49Shares Outstanding (diluted)
20.74M+4.1%Operating Expenses
$23.48MCash & Debt
$98.99MRevenue by Segment (annual)
$47.32MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $47.32M | $-40.36M | $-1.96 |
| 2024 | $31.62M | $-15.62M | $-0.77 |
| 2023 | $19.27M | $-12.65M | $-0.63 |
Valuation
SIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-20.00%Social Signal Score
Mentions (4)
- Newsprnewswire.com·26d ago·Negative
…ex Shoulder Reconstruction Procedures GRAND RAPIDS, Mich., Sept. 9, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations", or "the company") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it has entered into an exclusive collaboration with ALM Ortho, Inc. ("ALM Ortho"), a leader in additive manufacturing of titanium orthopedic implants, to introduce a bespoke implant for the treatm…
View source ↗ - Newsprnewswire.com·27d ago·Negative
…tlement of Patent Litigation with Catalyst OrthoScience GRAND RAPIDS, Mich., Sept. 8, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced that it has entered into a settlement agreement with Catalyst OrthoScience Inc. ("Catalyst") to resolve all outstanding patent litigation between the two companies.
View source ↗ - Newsprnewswire.com·57d ago·Neutral
Shoulder Innovations Promotes Jon Osborne to Chief Commercial Officer GRAND RAPIDS, Mich., Aug. 10, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the promotion of Jon Osborne to Chief Commercial Officer, effective August 6, 2026.
View source ↗ - Newsmarketbeat.com·58d ago·Neutral
Shoulder Innovations Q2 Earnings Call Highlights Shoulder Innovations NYSE: SI reported second-quarter net revenue of $17.2 million, up 56% from $11 million a year earlier, as the company added surgeons, expanded use among existing customers and advanced several product launches. The company raised its full-year 2026 revenue outlook to $67 million to $69 million, from a prior range of $65 million to $68 million.
View source ↗
Earnings
Typical surprise +3.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.46 vs $-0.46miss
- Wed, May 13$-0.41 vs $-0.44beat
- Tue, Mar 10$-0.38 vs $-0.42beat
- Tue, Nov 11$-0.48 vs $-0.37miss
- Tue, Sep 9$-0.64 vs $-0.01miss
Estimates and results for SI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SI officers and directors.
- Bought
- $9.9m
- Sold
- $5.5m
14 trades
17 trades
- Ball Robert Josephsold
- Gilde Healthcare Holding B.v.sold
- Gilde Healthcare Holding B.v.sold
- Gilde Healthcare Holding B.v.sold
- Gilde Healthcare Holding B.v.sold
- Ahearn Matthew Frasersold
- Ahearn Matthew Frasersold
- Ahearn Matthew Frasersold
69 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Chris Jacobshouse · NY27 · disclosed Dec 12, 2022 (34d later)Sell$1,001 - $15,000
- Chris Jacobshouse · NY27 · disclosed Sep 9, 2022 (53d later)Buy$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed Feb 3, 2022 (3d later)Buy$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed May 17, 2021 (178d later)Buy$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed Dec 2, 2020 (12d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.